Feature Channels:

Immunology

Add to Favorites Subscribe Share
Embargo will expire:
25-Feb-2020 7:00 AM EST
Released to reporters:
20-Feb-2020 4:25 PM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 25-Feb-2020 7:00 AM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: 224786_web.jpg

Colorectal cancer partner-in-crime identified

Hokkaido University

A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

Channels: All Journal News, Cancer, Genetics, Immunology,

Released:
20-Feb-2020 12:15 PM EST
Research Results
Newswise: John Theurer Cancer Center Launches Clinical Trial of Personalized Cancer Vaccine Using New Gene-Based Technology for High-Risk Melanoma

John Theurer Cancer Center Launches Clinical Trial of Personalized Cancer Vaccine Using New Gene-Based Technology for High-Risk Melanoma

Hackensack Meridian Health

John Theurer Cancer Center at Hackensack University Medical Center is the only site in New Jersey and one of just 17 in the country participating in a multicenter international Phase II study of an innovative personalized cancer vaccine being evaluated in combination with pembrolizumab immunotherapy in patients with melanoma that has been surgically removed but has a high risk of coming back. The hope is that the vaccine can prime a patient's immune system to be more responsive to immunotherapy and reduce the risk of cancer recurrence.

Channels: Cancer, Clinical Trials, Immunology, Personalized Medicine, Vaccines, Surgery,

Released:
20-Feb-2020 10:55 AM EST
Research Results
Newswise: UAH research into developing artificial lymph nodes has immunotherapy implications
  • Embargo expired:
    20-Feb-2020 10:00 AM EST

UAH research into developing artificial lymph nodes has immunotherapy implications

University of Alabama Huntsville

Research into engineering artificial organs that mimic the functions of human lymph nodes at The University of Alabama in Huntsville (UAH) has garnered one of its professors a $507,777 National Science Foundation (NSF) Faculty Early Career Development Program (CAREER) Award.

Channels: Cancer, Cell Biology, Immunology, Grant Funded News,

Released:
19-Feb-2020 1:05 PM EST
Announcement
Newswise: Scientists May Have a Way to Let Preemies Breathe Easier
  • Embargo expired:
    18-Feb-2020 11:00 AM EST

Scientists May Have a Way to Let Preemies Breathe Easier

Cincinnati Children's Hospital Medical Center

The continuing epidemic of pre-term birth includes this stark reality: tiny, fragile babies are born with underdeveloped lungs and prone to lifelong respiratory infections and related chronic illnesses. Cincinnati Children’s researchers report in Immunology the discovery of a complex biological process could in the development of cost effective treatments to help babies develop lifelong pulmonary resistance to respiratory infections.

Channels: Cell Biology, Children's Health, Infectious Diseases, Respiratory Diseases and Disorders, Immunology, All Journal News,

Released:
12-Feb-2020 1:45 PM EST
Research Results
Newswise: Targeting Turncoat Immune Cells to Treat Cancer

Targeting Turncoat Immune Cells to Treat Cancer

Ludwig Cancer Research

A Ludwig Cancer Research study has identified a mechanism by which regulatory T cells, which suppress immune responses, adapt their metabolism to thrive in the harsh microenvironment of the tumor.

Channels: All Journal News, Cancer, Immunology, National Institutes of Health (NIH), Nature (journal),

Released:
17-Feb-2020 11:00 AM EST
Research Results
Newswise: Cancer Immunotherapy Target Helps Fight Solid Tumors
  • Embargo expired:
    15-Feb-2020 7:00 AM EST

Cancer Immunotherapy Target Helps Fight Solid Tumors

Biophysical Society

Yvonne Chen engineers immune cells to target their most evasive enemy: cancer. New cancer immunotherapies generate immune cells that are effective killers of blood cancers, but they have a hard time with solid tumors.

Channels: Medical Meetings, All Journal News, Blood, Cancer, Immunology,

Released:
12-Feb-2020 12:20 PM EST
Research Results
PennMed_logo.png
  • Embargo expired:
    12-Feb-2020 5:00 PM EST
Released:
11-Feb-2020 2:40 PM EST
Research Results
Newswise: 223895_web.jpg
Released:
12-Feb-2020 3:10 PM EST
Research Results
  • Embargo expired:
    12-Feb-2020 2:00 PM EST

Designer Probiotic Treatment for Cancer Immunotherapy

Columbia University School of Engineering and Applied Science

Columbia Engineers have engineered probiotics to safely deliver immunotherapies within tumors, including nanobodies against two proven therapeutic targets—PD-L1 and CTLA-4. Continuously released by bacteria, the drugs continue to attack the tumor after just one dose, facilitating an immune response resulting in tumor regression. The versatile probiotic platform can also be used to deliver multiple immunotherapies simultaneously, enabling the release of effective therapeutic combinations within the tumor for more difficult-to-treat cancers like colorectal cancer.

Channels: All Journal News, Cancer, Immunology, Pharmaceuticals, National Institutes of Health (NIH),

Released:
10-Feb-2020 4:50 PM EST
Research Results


0.59039